Fundraising Fox

InkVivo

Lugano, CH · 1 known investors

InkVivo Technologies develops polymer-based drug delivery platforms (GARD/gastroretentive and SHEALD/injectable) for controlled, localized, and sustained release of small molecules and biologics. An ETH Zurich spin-off, it works with pharmaceutical and nutraceutical partners to improve bioavailability and patient adherence, with programs targeting iron deficiency anemia and neurodegenerative diseases.

BiotechDeep TechMedical DevicesNew Materials

Founders & leadership

EG
Elia GuzziCo-Founder & CEO
SC
Stefano CeruttiCo-Founder & COO
LTLeonardo Tognola
Leonardo TognolaCo-Founder & CTO

Investors · 1

TiVenture SALugano

Competitors · 1

by search overlap
Northwest Biotherapeutics5 shared keywordsNorthwest Biotherapeutics is a clinical-stage biotechnology company developing personalized cancer vaccines, marketed under the DCVax platform, that use activated dendritic cells to treat a range of solid tumor cancers. Its product lines include DCVax-L, DCVax-Direct, and DCVax-Prostate.

Companies competing with InkVivo for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does InkVivo do?
InkVivo Technologies develops polymer-based drug delivery platforms (GARD/gastroretentive and SHEALD/injectable) for controlled, localized, and sustained release of small molecules and biologics. An ETH Zurich spin-off, it works with pharmaceutical and nutraceutical partners to improve bioavailability and patient adherence, with programs targeting iron deficiency anemia and neurodegenerative diseases.
Who founded InkVivo?
InkVivo was founded by Elia Guzzi, Stefano Cerutti, Leonardo Tognola.
Who are InkVivo's investors?
InkVivo's investors include TiVenture SA.
Where is InkVivo headquartered?
InkVivo is headquartered in Lugano, CH.